PhalconBio develops engineered bacteriophage therapeutics that deliver antibacterial proteins directly to pathogenic bacteria, providing a precision‑targeted alternative to traditional antibiotics. Their platform enhances phage efficacy, reduces resistance emergence, and improves biofilm penetration, with a lead program against pulmonary Pseudomonas aeruginosa infections. The technology is adaptable to other high‑risk ESKAPEE pathogens, aiming to expand the antimicrobial pipeline.
Funding
Funding not disclosed
Founders
Product
Problem
Antibiotic resistance is a growing global threat, with few new classes of antibiotics developed in recent decades. Infections caused by resistant bacteria, such as Pseudomonas aeruginosa, are increasingly difficult to treat, leading to severe disease, chronic conditions, and high mortality rates, especially in patients with compromised lung function. Traditional broad-spectrum antibiotics can also disrupt the microbiome and promote further resistance.
Solution
PhalconBio is developing precision antibacterial therapies based on its engineered phage therapeutics (EPTs) platform to combat antibiotic-resistant infections. The company's EPTs are genetically enhanced bacteriophages that specifically target and eliminate pathogenic bacteria while minimizing harm to beneficial bacteria. These engineered phages integrate precision targeting with phage-mediated delivery of antibacterial effector proteins, reprogramming bacteria to produce secondary antimicrobials at the infection site. PhalconBio's lead program focuses on pulmonary Pseudomonas aeruginosa infections, offering a targeted alternative to traditional antibiotics for patients with chronic lung diseases and hospital-acquired pneumonia.
Target Audience
The primary target audience includes patients with chronic structural lung diseases (such as bronchiectasis, cystic fibrosis, and primary ciliary dyskinesia) and those with acute hospital-acquired or ventilator-associated pneumonia, as well as pharmaceutical and biotech companies seeking innovative antimicrobial solutions.
Features
- Genetically engineered bacteriophages for targeted bacterial elimination
- Phage-mediated delivery of antibacterial effector proteins
- Induction of secondary antimicrobial production at the infection site
- Enhanced efficacy against antibiotic-resistant strains
- Minimized disruption of the microbiome
- Improved biofilm targeting
- Adaptable platform for addressing other ESKAPEE pathogens